Glucagaon-like peptide (GLP-1) and Adipose Tissue Inflammation in Obesity Study

INTERVENTION: Arm1. Intravenous infusion of glucagon‐like peptide (GLP‐1) at a dose of 0.9 pmol/kg/min. The GLP‐1 will be obtained from Bachem AG in sealed vials (Clinalfa). The GLP‐1 will be infused for 240 min into fasted individuals in the early morning. Plasma concentrations of GLP‐1 will be measured. Arm2. Infusion of 0.9% saline as a control. There will be a 3 week washout period between treatments in an individual to prevent carryover from one treatment to the next. CONDITION: Obesity PRIMARY OUTCOME: Adipose tissue content of IL‐6, tumor necrosis factor‐a, and monocyte chemotactic protein‐1. This is a composite primary endpoint. Adipose tissue mRNA levels of interleukin‐6, tumor necrosis factor‐a, and monocyte chemotactic protein‐1. This is a composite primary outcome. Plasma concentrations of interleukin‐6 (IL‐6). SECONDARY OUTCOME: Adipose tissue mRNA levels of adipocyte differentiation markers. Adipose tissue macrophage numbers. Circulating monocyte activation markers CD14/CD16 will be measured by FACS after separation of cells from plasma. INCLUSION CRITERIA: Body mass index>30 kg/m2